Studies under way into whether third dose of coronavirus vaccine would help immunity

Studies are under way into how effective a third shot of the Pfizer/BioNTech vaccine could be in increasing the immune response against coronavirus.

Researchers will be examining whether having a second booster dose would offer more protection in cases of COVID-19 caused by existing and also new variants of the virus – like the one first found in South Africa.

Real-world data from Israel’s health ministry recently suggested the risk of becoming ill with coronavirus falls by 95.8% after two Pfizer jabs.

The vaccine was also 98% effective in preventing breathing problems or a fever and 98.9% effective in preventing hospitalisations and death, the ministry added.

Follow live COVID-19 updates from the UK and around the world

Speaking to NBC on Thursday, Pfizer chief executive Albert Bourla said: “We believe that the third dose will raise the antibody response 10 to 20 fold.”

People who took part in the original phase one or two trials and who are trialling a third shot will get their new jab six to 12 months after their initial set of injections.

More from Covid-19

  • Rat sightings on the rise in London as businesses remain closed during lockdown

  • COVID-19: ‘Teachers know us better than an algorithm’ – students support exam grades decision

  • COVID-19: UK alert level downgraded as threat of NHS being overwhelmed recedes

  • COVID-19: Major cities falling well behind in UK’s bid to vaccinate its way out of lockdown

  • COVID-19: UK reports another 323 coronavirus deaths and 9,985 cases – as first jab count tops 18.6 million

  • COVID-19: Anti-fraud probe as EU nations are offered 900 million ‘ghost’ jabs for €12.7bn

The third shot will be exactly the same as what participants got before.

The study will include 144 people spread across the age groups of 18-55 and 65-85 in the United States.

Separately the Pfizer/BioNTech teams are in talks with regulatory bodies – like the US Food and Drug Administration (FDA) and the European Medicines Agency – about potential studies into new forms of their coronavirus vaccine.

These would involve testing a new makeup of the jab based on the B.1.351 South Africa variant.

As an mRNA vaccine, the Pfizer/BioNTech jab trains the body to fight infection by injecting a harmless part of the virus into the body to train our defences to fight it.

If these studies go ahead, Pfizer and BioNTech say it will help put them in a position to quickly update their vaccines depending on the strains that appear.

Pfizer/BioNTech vaccine. Pic:AP
Image:Pfizer’s jab is one of two vaccines that have been widely rolled out across the UK. Pic: AP

Ugur Sahin, chief executive and co-founder of BioNTech, said: “Our proactive clinical development strategy aims to create the foundation today, that will enable us to address the challenges of tomorrow.

“We want to be prepared for different scenarios.”

Pfizer chief scientific officer Mikael Dolsten said COVID vaccines may end up in a similar situation to flu jabs.

He said: “The rate of mutations in the current virus is higher than expected.

“It’s a reasonable probability that we would end up with regular boosts. And for potent vaccines, it may be that you need to do a strain change every few years, but not necessarily every year.”

Pfizer vaccine is highly effective at preventing serious illness or death - data

Pfizer vaccine is highly effective at preventing serious illness or death – data

Mr Bourla added: “A likely scenario is that we will not have a three dose vaccine.

“We will have an annual revaccination, likely with one dose of the vaccine.

“And that could be an annual booster either with the same vaccine or, if there is a change in the variant, with an adapted to the new variant vaccine.”

Moderna, another vaccine maker, had previously announced it was set to start tests on new versions of its jabs adapted to target variants of the coronavirus.

Mark Gibson

Graduates in Northwestern University, Evanston, Illinois 1990. Move to Los Angeles California in 2004. Specialized in Internet journalism.

Leave a Reply

Your email address will not be published. Required fields are marked *